As previously reported, Leerink analyst Andrew Berens upgraded Epizyme to Outperform from Market Perform after the company disclosed agreement with FDA over plans to seek accelerated approval of tazemetostat in both EZH2 mutant and wild-type follicular lymphoma as part of the same filing based on the current data set. The updated regulatory plan, and management confidence, raises his conviction in the potential for tazemetostat to be approved in a broader population. Additionally, Berens increased his probability of success for both mutant and wild-type patients, and now models commercial uptake in both settings in 2020. The analyst also raised his price target on the shares to $12 from $11.